Peter Macdonald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10460584/publications.pdf

Version: 2024-02-01

56 papers	3,715 citations	236925 25 h-index	161849 54 g-index
57 all docs	57 docs citations	57 times ranked	4744 citing authors

#	Article	IF	Citations
1	Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes. Journal of Heart and Lung Transplantation, 2022, 41, 334-344.	0.6	21
2	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. JAMA Cardiology, 2022, 7, 26.	6.1	59
3	Heart Transplant Donor Selection: Recent Insights. Current Transplantation Reports, 2022, 9, 12.	2.0	0
4	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.	27.0	381
5	Swallowing and laryngeal complications in lung and heart transplantation: Etiologies and diagnosis. Journal of Heart and Lung Transplantation, 2021, 40, 1483-1494.	0.6	9
6	Oropharyngeal dysphagia and laryngeal dysfunction after lung and heart transplantation: A systematic review. Disability and Rehabilitation, 2020, 42, 2083-2092.	1.8	8
7	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	7.1	47
8	Successful transplantation of high-risk cardiac allografts from DCD donors following ex vivo coronary angiography. Journal of Heart and Lung Transplantation, 2020, 39, 1496-1499.	0.6	8
9	DCD donations and outcomes of heart transplantation: the Australian experience. Indian Journal of Thoracic and Cardiovascular Surgery, 2020, 36, 224-232.	0.6	38
10	Donor heart and lung procurement: A consensus statement. Journal of Heart and Lung Transplantation, 2020, 39, 501-517.	0.6	100
11	Clinical predictors for oropharyngeal dysphagia and laryngeal dysfunction after lung and heart transplantation. International Journal of Language and Communication Disorders, 2019, 54, 894-901.	1.5	6
12	Banked blood for normothermic machine perfusion of the donor heart: A clinical perspective. Journal of Heart and Lung Transplantation, 2019, 38, 1322.	0.6	8
13	Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis. British Journal of Clinical Pharmacology, 2019, 85, 2772-2783.	2.4	11
14	Outcomes of Donation After Circulatory Death Heart Transplantation in Australia. Journal of the American College of Cardiology, 2019, 73, 1447-1459.	2.8	172
15	Heart transplantation from donation-after-circulatory-death (DCD) donors: Back to the futureâ€•Evolving trends in heart transplantation from DCD donors. Journal of Heart and Lung Transplantation, 2019, 38, 599-600.	0.6	20
16	An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms. Journal of Heart and Lung Transplantation, 2019, 38, 636-646.	0.6	43
17	Exploring the cardiac response to injury in heart transplant biopsies. JCI Insight, 2018, 3, .	5.0	43
18	Research priority setting in organ transplantation: a systematic review. Transplant International, 2017, 30, 327-343.	1.6	30

#	Article	IF	Citations
19	Dilated cardiomyopathy. Lancet, The, 2017, 390, 400-414.	13.7	445
20	How do you mend a donor heart?. Journal of Heart and Lung Transplantation, 2017, 36, 604-606.	0.6	1
21	Enhanced Recovery of Donation After Circulatory Death (DCD) Hearts Using Ante-Mortem Heparin and Supplemented Celsior in a Rodent Model. Heart Lung and Circulation, 2017, 26, S361.	0.4	1
22	Banked Blood in the Recovery of Donation after Circulatory Death (DCD) Hearts in a Porcine Model. Heart Lung and Circulation, 2017, 26, S392.	0.4	1
23	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, The, 2016, 388, 2895-2903.	13.7	229
24	Ex-Vivo Perfusion of Marginal Donor Hearts: Is normal allograft function assured post-transplant?. Heart Lung and Circulation, 2016, 25, e92.	0.4	1
25	Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines. Current Cardiology Reviews, 2016, 12, 166-179.	1.5	3
26	Ethical Guidelines for Organ Transplantation from Deceased Donors. Heart Lung and Circulation, 2015, 24, 633-634.	0.4	2
27	An Absolute Risk Prediction Model to Determine Unplanned Cardiovascular Readmissions for Adults with Chronic Heart Failure. Heart Lung and Circulation, 2015, 24, 1068-1073.	0.4	32
28	Composite outcome measures in a pragmatic clinical trial of chronic heart failure management: A comparative assessment. International Journal of Cardiology, 2015, 185, 62-68.	1.7	11
29	Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. Lancet, The, 2015, 385, 2585-2591.	13.7	345
30	Latest Developments in Heart Transplantation: A Review. Clinical Therapeutics, 2015, 37, 2234-2241.	2.5	20
31	Size and Gender Matching in Heart Transplantation â€“ Optimizing Donor Utilization in an Era of Changing Donor and Recipient Characteristics. Current Transplantation Reports, 2014, 1, 266-272.	2.0	8
32	Primary Graft Dysfunction After Heart Transplantation. Current Transplantation Reports, 2014, 1, 257-265.	2.0	20
33	Ex Vivo Coronary Angiographic Evaluation of a Beating Donor Heart. Circulation, 2014, 130, e341-3.	1.6	16
34	Are all outcomes in chronic heart failure rated equally? An argument for a patient-centred approach to outcome assessment. Heart Failure Reviews, 2014, 19, 153-162.	3.9	13
35	Organ Allocation Around the World: Insights From the ISHLT International Registry for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 975-984.	0.6	38
36	Prolonged impact of home versus clinic-based management of chronic heart failure: Extended follow-up of a pragmatic, multicentre randomized trial cohort. International Journal of Cardiology, 2014, 174, 600-610.	1.7	32

#	Article	IF	Citations
37	Report from a consensus conference on primary graft dysfunction after cardiac transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 327-340.	0.6	523
38	What is the methodological and reporting quality of health related quality of life in chronic heart failure clinical trials?. International Journal of Cardiology, 2013, 164, 133-140.	1.7	8
39	Patient, provider and system factors influencing rehospitalisation in adults with heart failure. Contemporary Nurse, 2013, 43, 244-256.	1.0	4
40	Functional Characterization of a Novel Mutation in NKX2-5 Associated With Congenital Heart Disease and Adult-Onset Cardiomyopathy. Circulation: Cardiovascular Genetics, 2013, 6, 238-247.	5.1	77
41	Impact of Home Versus Clinic-Based Management of Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 60, 1239-1248.	2.8	119
42	The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure. Heart Lung and Circulation, 2012, 21, 260-266.	0.4	12
43	A Randomised, Placebo-controlled Trial of Carvedilol in Early Familial Dilated Cardiomyopathy. Heart Lung and Circulation, 2011, 20, 566-573.	0.4	16
44	The WHICH? trial: rationale and design of a pragmatic randomized, multicentre comparison of homeâ€• vs. clinicâ€based management of chronic heart failure patients. European Journal of Heart Failure, 2011, 13, 909-916.	7.1	35
45	Granulocyte-colony stimulating factor in refractory ischemic heart disease: Throwing stones from glass houses. American Heart Journal, 2009, 157, e39.	2.7	0
46	The role of b-type natriuretic peptide in heart failure management. Australian Critical Care, 2009, 22, 117-123.	1.3	15
47	Nebulized Furosemide for the Management of Dyspnea: Does the Evidence Support Its Use?. Journal of Pain and Symptom Management, 2008, 36, 424-441.	1.2	50
48	Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: The G-CSF in Angina patients with IHD to stimulate Neovascularization (GAIN I) trial. American Heart Journal, 2008, 156, 954-963.	2.7	31
49	Cultural diversity In heart failure management: Findings from the Discover Study (Part 2). Contemporary Nurse, 2007, 25, 50-62.	1.0	45
50	Mutations in Cardiac T-Box Factor Gene TBX20 Are Associated with Diverse Cardiac Pathologies, Including Defects of Septation and Valvulogenesis and Cardiomyopathy. American Journal of Human Genetics, 2007, 81, 280-291.	6.2	317
51	Profound thrombocytopenia related to G-CSF. American Journal of Hematology, 2007, 82, 229-230.	4.1	21
52	Increases in leukocyte cluster of differentiation antigen expression during cardiopulmonary bypass in patients undergoing heart transplantation. Proteomics, 2004, 4, 1918-1926.	2.2	15
53	A case for consideration of cultural diversity in heart failure management â€•Part 1: Rationale for the DISCOVER Study. Contemporary Nurse, 2004, 17, 204-210.	1.0	13
54	Diuretic therapy in chronic heart failure: Implications for heart failure nurse specialists. Australian Critical Care, 2003, 16, 59-69.	1.3	4

#	Article	IF	Citations
55	Protective Effect of Short-Term Calcitriol or Cyclical Etidronate on Bone Loss After Cardiac or Lung Transplantation. Journal of Bone and Mineral Research, 2001, 16, 565-571.	2.8	73
56	Effect of Calcitriol on Bone Loss After Cardiac or Lung Transplantation. Journal of Bone and Mineral Research, 2000, 15, 1818-1824.	2.8	113